PKComb-BOIN12: A Pharmacokinetically Guided Bayesian Design for Dose Optimisation in Oncology Drug-Combination Trials
Dose optimisation of two-agent combinations in early-phase oncology trials must jointly balance toxicity, efficacy, and pharmacologically meaningful drug exposure, yet existing model-assisted combination designs use only binary toxicity--efficacy outcomes and leave pharmacokinetic (PK) data unused for dosing decisions. We propose PKComb-BOIN12, a utility-based Bayesian optimal interval design embedding a continuous PK exposure metric into two-agent dose optimisation via a PK-guided escalation rule and a PK-sufficiency constraint on the final admissible set. Two contributions distinguish this…
Comments and reviews
No comments yet.
API
curl /api/v1/records/arxiv/2610.05477
curl -X POST /api/v1/records/arxiv/2610.05477/vote -H "Authorization: Bearer $KEY" -H "Content-Type: application/json" \
-d '{"value": 1, "emoji": "🤔", "note": "optional"}'
curl -X POST /api/v1/records/arxiv/2610.05477/comments -H "Authorization: Bearer $KEY" -H "Content-Type: application/json" \
-d '{"body": "…", "review": true}'